(Q38027791)

27 August 2017

title

Disease modifying drugs targeting β-amyloid (English)

1 reference

27 August 2017

S N Ozudogru

1

1 reference

27 August 2017

C F Lippa

series ordinal

2

1 reference

27 August 2017

language of work or name

English

0 references

publication date

1 August 2012

1 reference

American Journal of Alzheimer's Disease & Other Dementias

27 August 2017

published in

1 reference

27 August 2017

volume

27

1 reference

27 August 2017

issue

5

1 reference

27 August 2017

page(s)

296-300

1 reference

Hydrogen peroxide promotes Abeta production through JNK-dependent activation of gamma-secretase

27 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1177%2F1533317512452034

Mild cognitive impairment: clinical characterization and outcome

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1533317512452034

Nonpharmacological therapies in Alzheimer's disease: a systematic review of efficacy

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1533317512452034

Mice lacking both presenilin genes exhibit early embryonic patterning defects

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1533317512452034

Phase 2 safety trial targeting amyloid beta production with a gamma-secretase inhibitor in Alzheimer disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1533317512452034

NerveCenter: Phase III Alzheimer trial halted: Search for therapeutic biomarkers continues

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1533317512452034

γ-secretase inhibitors and modulators for the treatment of Alzheimer's disease: disappointments and hopes

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1533317512452034

Dynamics of Aβ42 reduction in plasma, CSF and brain of rats treated with the γ-secretase modulator, GSM-10h

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1533317512452034

Treating transgenic Alzheimer mice with a β-secretase inhibitor, what have we learned?

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1533317512452034

beta-Secretase as a therapeutic target for Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1533317512452034

Beta-secretase inhibitor GRL-8234 rescues age-related cognitive decline in APP transgenic mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1533317512452034

Potent BACE-1 inhibitor design using pharmacophore modeling, in silico screening and molecular docking studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1533317512452034

A noncompetitive BACE1 inhibitor TAK-070 ameliorates Abeta pathology and behavioral deficits in a mouse model of Alzheimer's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1533317512452034

BACE: Therapeutic target and potential biomarker for Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1533317512452034

Function, regulation and therapeutic properties of beta-secretase (BACE1).

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1533317512452034

Subacute meningoencephalitis in a subset of patients with AD after Abeta42 immunization

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1533317512452034

Abeta42 immunization in Alzheimer's disease generates Abeta N-terminal antibodies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1533317512452034

Therapeutically effective antibodies against amyloid-beta peptide target amyloid-beta residues 4-10 and inhibit cytotoxicity and fibrillogenesis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1533317512452034

A single ascending dose study of bapineuzumab in patients with Alzheimer disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1533317512452034

A phase 2 multiple ascending dose trial of bapineuzumab in mild to moderate Alzheimer disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1533317512452034

Common features between diabetes mellitus and Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1533317512452034

Impaired insulin and insulin-like growth factor expression and signaling mechanisms in Alzheimer's disease – is this type 3 diabetes?

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1533317512452034

GLP-1 receptor stimulation reduces amyloid-beta peptide accumulation and cytotoxicity in cellular and animal models of Alzheimer's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1533317512452034

Glucagon-like peptide-1 decreases endogenous amyloid-beta peptide (Abeta) levels and protects hippocampal neurons from death induced by Abeta and iron.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1533317512452034

Statins are associated with a reduced risk of Alzheimer disease regardless of lipophilicity. The Rotterdam Study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1533317512452034

Statins promote the degradation of extracellular amyloid {beta}-peptide by microglia via stimulation of exosome-associated insulin-degrading enzyme (IDE) secretion

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1533317512452034

Randomized controlled trial of atorvastatin in mild to moderate Alzheimer disease: LEADe

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1533317512452034

Protective effects of NSAIDs on the development of Alzheimer disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1533317512452034

Ibuprofen reduces Abeta, hyperphosphorylated tau and memory deficits in Alzheimer mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1533317512452034

Ibuprofen attenuates oxidative damage through NOX2 inhibition in Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1533317512452034

Cognitive function over time in the Alzheimer's Disease Anti-inflammatory Prevention Trial (ADAPT): results of a randomized, controlled trial of naproxen and celecoxib

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1533317512452034

Novel γ-secretase modulators: a review of patents from 2008 to 2010.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1533317512452034

Something old... something blue.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1533317512452034

Pharmacokinetics and organ distribution of intravenous and oral methylene blue.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1533317512452034

Methylene blue reduces aβ levels and rescues early cognitive deficit by increasing proteasome activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1533317512452034

21 January 2018

Identifiers

DOI

10.1177/1533317512452034

1 reference

27 August 2017

1 reference